SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Spyre Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$84.72+4.82 (+6.03%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Spyre Therapeutics has not reported a dividend
No dividend per share appears in Spyre Therapeutics's annual filings since fiscal 2013.